Drug interactions with statins

Abstract The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally well tolerated as monotherapy. Statins are associated with two important adverse effects, asymptomatic elevation in liver enzymes and myopathy. Myopathy is most likely to occur when statins are administered with other drugs. Statins are substrates of multiple drug transporters (including OAT- -P1B1, BCRP and MDR1) and several cytochrome P450 (CYP) enzymes (including CYP3A4, CYP2C8, CYP2C19, and CYP2C9). Possible adverse effects of statins can occur due to interactions in concomitant use of drugs that substantially inhibit or induce their methabolic pathway. This review summarizes the most important interactions of statins.

• Publication year

  2013

• Venue

  Acta Pharmaceutica

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2478/acph-2013-0022PMID 24152892
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CONCOMITANT USE OF SIMVASTATIN AND AMIODARONE RESULTING IN SEVERE RHABDOMYOLYSIS: A CASE REPORT AND REVIEW OF THE LITERATURE

  2011cited by this paper
• Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients

  2011cited by this paper
• [Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole].

  2011cited by this paper
• Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin

  2011cited by this paper
• In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions

  2011cited by this paper
• Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.

  2011cited by this paper
• Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro

  2010cited by this paper
• Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics.

  2010cited by this paper
• Results of a Safety Initiative for Patients on Concomitant Amiodarone and Simvastatin Therapy in a Veterans Affairs Medical Center

  2010cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.

  2009cited by this paper
• Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.

  2009cited by this paper
• Comprar Martindale the complete reference 36th Ed, 2 vols + CD-ROM | Sean Sweetman | 9780853698425 | Pharmaceutical Press

  2009cited by this paper
• Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.

  2009cited by this paper
• Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study

  2009cited by this paper
• Concurrent use of statins and amiodarone.

  2009cited by this paper
• Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers

  2009cited by this paper
• The SLCO1B1*5 genetic variant is associated with statin-induced side effects.

  2009cited by this paper
• Statins and phenytoin interact - a case history.

  2008cited by this paper
• Interaction between statins and clopidogrel: is there anything clinically relevant?

  2008cited by this paper
• Clinical Reasoning: Rhabdomyolysis after combined treatment with simvastatin and fluconazole

  2008cited by this paper
• Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.

  2008cited by this paper
• Rhabdomyolysis induced by simvastatin-fluconazole combination.

  2008cited by this paper
• [Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient].

  2008cited by this paper
• SLCO1B1 variants and statin-induced myopathy--a genomewide study.

  2008cited by this paper
• Corticosteroid Interactions with Cyclosporine, Tacrolimus, Mycophenolate, and Sirolimus: Fact or Fiction?

  2008cited by this paper
• The Role of Cytochrome P2C19 in R-warfarin Pharmacokinetics and its Interaction With Omeprazole

  2008cited by this paper
• Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid

  2007cited by this paper
• Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy

  2007cited by this paper
• Severe Rhabdomyolysis and Acute Renal Failure Secondary to Concomitant Use of Simvastatin, Amiodarone, and Atazanavir

  2007cited by this paper
• The Influence of Macrolide Antibiotics on the Uptake of Organic Anions and Drugs Mediated by OATP1B1 and OATP1B3

  2007cited by this paper
• Probable Warfarin–Simvastatin Interaction

  2007cited by this paper
• Esterase Inhibition by Grapefruit Juice Flavonoids Leading to a New Drug Interaction

  2007cited by this paper
• Effects of treatment with a commercially available St John's Wort product (Movina®) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin

  2007cited by this paper
• A lesson for everyone in drug-drug interactions.

  2007cited by this paper
• [Interactions between statins and macrolide antibiotics].

  2007cited by this paper
• Effect of benidipine on simvastatin metabolism in human liver microsomes.

  2007cited by this paper
• Simvastatin-Induced Rhabdomyolysis Following Cyclosporine Treatment for Uveitis

  2007cited by this paper
• Abstract 3287: Lack of Evidence of a Clopidogrel-Statin Interaction in the CHARISMA Trial

  2006cited by this paper
• Strategies for management and treatment of dyslipidemia in HIV/AIDS

  2006cited by this paper
• The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study.

  2006cited by this paper
• Rhabdomyolysis associated with pomegranate juice consumption.

  2006cited by this paper
• Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108

  2006cited by this paper
• Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects.

  2006cited by this paper
• Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems

  2006cited by this paper
• The impact of simvastatin on warfarin disposition and dose requirements

  2006cited by this paper
• Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

  2006cited by this paper
• DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1

  2006cited by this paper
• Simvastatin–Amiodarone Interaction Resulting in Rhabdomyolysis, Azotemia, and Possible Hepatotoxicity

  2006cited by this paper
• Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma

  2005cited by this paper
• CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B

  2005cited by this paper
• Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis.

  2005cited by this paper
• Simvastatin Interaction with Clarithromycin and Amiodarone Causing Myositis

  2005cited by this paper
• The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease

  2005cited by this paper
• Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin.

  2005cited by this paper
• Adverse events with concomitant amiodarone and statin therapy.

  2005cited by this paper
• A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy.

  2004cited by this paper
• An open‐label study on the pharmacokinetics (PK) of pitavastatin (NK‐104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers

  2004cited by this paper
• Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions

  2004cited by this paper
• Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin.

  2004cited by this paper
• Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study

  2004cited by this paper
• Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

  2004cited by this paper
• Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.

  2004cited by this paper
• Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics

  2004cited by this paper
• High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).

  2004cited by this paper
• Atorvastatin Does Not Affect the Antiplatelet Potency of Clopidogrel When It Is Administered Concomitantly for 5 Weeks in Patients With Acute Coronary Syndromes

  2004cited by this paper
• Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese.

  2004cited by this paper
• Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.

  2004cited by this paper
• Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A

  2003cited by this paper
• Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.

  2003cited by this paper
• Two cases of rhabdomyolysis associated with high-dose simvastatin.

  2003cited by this paper
• Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance

  2003cited by this paper
• Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction

  2003cited by this paper
• Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.

  2003cited by this paper
• Simvastatin–Fluconazole Causing Rhabdomyolysis

  2003cited by this paper
• INTERACTION BETWEEN FIBRATES AND STATINS - METABOLIC INTERACTIONS WITH GEMFIBROZIL

  2003cited by this paper
• Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer.

  2003cited by this paper
• The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements

  2003cited by this paper
• Effects of Statins on Platelet Inhibition by a High Loading Dose of Clopidogrel

  2003cited by this paper
• Risk for myopathy with statin therapy in high-risk patients.

  2003cited by this paper
• Statin-associated myopathy.

  2003cited by this paper
• Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

  2002cited by this paper
• Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.

  2002cited by this paper
• Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047

  2002cited by this paper
• A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers

  2002cited by this paper
• Safety considerations for statins

  2002cited by this paper
• A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin

  2002cited by this paper
• Rhabdomyolysis with Concurrent Atorvastatin and Diltiazem

  2002cited by this paper
• Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.

  2002cited by this paper
• Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.

  2002cited by this paper
• Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.

  2001cited by this paper
• Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin

  2001cited by this paper
• Pharmacokinetic Interactions between Nelfinavir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Simvastatin

  2001cited by this paper
• Rhabdomyolysis Associated with Concurrent Use of Simvastatin and Diltiazem

  2001cited by this paper
• Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

  2001cited by this paper
• Inhibition of In Vitro Metabolism of Simvastatin by Itraconazole in Humans and Prediction of In Vivo Drug-Drug Interactions

  2001cited by this paper
• Plasma concentrations of active simvastatin acid are increased by gemfibrozil

  2000cited by this paper
• The interaction of diltiazem with simvastatin

  2000cited by this paper

• The Effect of Cytochrome P450 and Organic Anion Transporter Polypeptide on Macrolides–Atorvastatin Drug Interaction

  2025cites this paper
• Artificial intelligence to predict inhibitors of drug-metabolizing enzymes and transporters for safer drug design

  2025cites this paper
• Expression, Function, and Regulation of ABCG2 on the Intestinal Epithelial Barrier Permeability.

  2025cites this paper
• Pharmacovigilance analysis of myopathy associated with azoles and nonstatins interactions based on US FAERS database

  2025cites this paper
• Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration

  2024cites this paper
• Improvement mechanism of lipid metabolism and gut microbiota in obese mice with Thunnus albacares eggs yolk glycoprotein

  2024cites this paper
• Effect of berberine on pharmacokinetics and pharmacodynamics of atorvastatin in hyperlipidemia rats

  2023cites this paper
• Mathematical Modelling of the Effects of Statins on the Growth of Necrotic Core in Atherosclerotic Plaque

  2023cites this paper
• In vitro validation of an in vivo phenotyping drug cocktail for major drug transporters in humans.

  2023cites this paper
• Statins—From Fungi to Pharmacy

  2023cites this paper
• Current and future options in cholesterol lowering treatments.

  2023cites this paper
• Molecular targets of statins and their potential side effects: Not all the glitter is gold.

  2022cites this paper
• Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond

  2022cites this paper
• Special Section on Drug Metabolism in Liver Injury and Repair — Minireview Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond

  2022cites this paper
• Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome

  2022cites this paper
• Hypercholesterolemia reduces the expression and function of hepatic drug metabolizing enzymes and transporters in rats.

  2022cites this paper
• Formulation and Evaluation of Nanosuspension as an Alternative Approach for Solubility Enhancement of Simvastatin

  2021cites this paper
• Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs.

  2020cites this paper
• Republished: An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase

  2020cites this paper
• An Update on Pharmacotherapy of Dyslipidemia for Adults

  2020cites this paper
• An unusually impressive atorvastatin-induced elevation of serum alkaline phosphatase

  2020cites this paper
• A multi-enzyme strategy for the production of a highly valuable lactonized statin side-chain precursor

  2020cites this paper
• Biocatalysis for the Production of Pharmaceutical Intermediates

  2019cites this paper
• Application of nanotechnology to improve the therapeutic benefits of statins.

  2019cites this paper
• Inhibitory effect of simvastatin in nasopharyngeal carcinoma cells

  2019cites this paper
• Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes

  2019cites this paper
• A Brief Drug Class Review: Considerations for Statin Use, Toxicity, and Drug Interactions

  2018cites this paper
• In vitro antibacterial effects of statins against bacterial pathogens causing skin infections

  2018cites this paper
• Metabolic Drug Interactions with Immunosuppressants

  2018cites this paper
• Computational Toxicology for Traditional Chinese Medicine

  2018cites this paper
• Statin-induced liver and muscle toxicities

  2018cites this paper
• Statins: a viable candidate for host-directed therapy against infectious diseases

  2018cites this paper
• Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update

  2018cites this paper
• Drug-drug interactions: experience at a tertiary care hospital

  2017cites this paper
• Oxidative Drug Metabolism by Mammalian Cytochrome P450 Enzymes Using Their Monooxygenase and Peroxygenase Functions

  2017cites this paper
• Assessment of clopidogrel discontinuation rates following pharmacogenomic testing in a high-risk patient population : an interim analysis of the UPGRADE Registry

  2017cites this paper
• Myotoxicity of statins: Mechanism of action

  2017cites this paper
• Statins: All you need to know

  2017cites this paper
• Epidemiology and management of hyperlipidemia.

  2017cites this paper
• Utjecaj genskih polimorfizama na terapijski učinak statina

  2016cites this paper
• Current and Emerging Uses of Statins in Clinical Therapeutics: A Review

  2016cites this paper
• Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination?

  2015cites this paper
• The association between donor and recipient statin use and infections after allogeneic hematopoietic cell transplantation

  2015cites this paper
• The effect of atorvastatin treatment on serum oxysterol concentrations and cytochrome P450 3A4 activity.

  2015cites this paper
• Are statins a viable option for the treatment of infections with the hepatitis C virus?

  2014cites this paper
• More ethical and more efficient clinical research

  2014cites this paper
• More ethical and more efficient clinical research: multiplex trial design

  2014cites this paper
• Statin Intolerance: A Mini Review

  year unknowncites this paper